维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Hanfang Bi"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination显示文摘Mass application of SARS-CoV-2 vaccines is a major approach to reduce SARS-CoV-2 transmission and COVID19 symptoms worldwide.The inactivated SARS-CoV-2 vaccine is one of the most widely administered vaccine types in many countries,with over 2 billion doses administered as of 31 August 2021.However,clinical trials estimate 65%–85%protection from detectable symptoms for inactivated SARS-CoV-2 vaccines[1–4],with 15%–35%of people remaining insufficiently protected after two-dose immunization.Immune protectionforthese‘non-responders’is critical for population immunity as established by mass vaccination.A third dose of inactivated(CoronaVac)vaccine has been shown to boost antibody response by between 3–5 folds in the general population[5].Whether a third dose can induce an adequate antibody response in‘non-responders’remains unclear.Here we report a trial of a third dose in a cohort of 105 vaccinated participants(Supplementary Fig.S1)with suboptimal antibody responses(non-responders)aftertwo doses(43.8%were men;average age 43±11 years[±SD];average BMI 23.5±3.4[±SD],Supplementary Table S1).	Taicheng Zhou Tianpei Shi Ao Li Lingzhi Zhu Xinshuai Zhao Naiyin Mao Wanting Qin Hanfang Bi Mei Yang Muxian Dai Fengwei Liu Rong Wang Wei Su Liang Zhang Wenbo Xu Jia Wei Zijie Zhang	2022	National Science Review2022，9，7：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费